Hematopoietic stem cell transplantation in multiple sclerosis

Area of Science:

• Neuroimmunology
• Hematology
• Transplantation Medicine

Background:

• Severe multiple sclerosis (MS) poses significant challenges for conventional therapies.
• Hematopoietic stem cell transplantation (HSCT) has emerged as a potential treatment option for refractory MS.
• Understanding the long-term efficacy and safety of HSCT in MS is crucial.

Purpose of the Study:

• To comprehensively review the outcomes of hematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) patients.
• To evaluate the effectiveness of HSCT in stabilizing or improving MS progression.
• To analyze factors influencing HSCT outcomes, including patient selection and conditioning regimens.

Main Methods:

• Systematic review of single-center and multicenter studies on HSCT for MS.
• Monitoring of patient characteristics, transplantation procedures, toxicity, and clinical outcomes.
• Comparison of results across different studies and patient cohorts.

Main Results:

• Stabilization or improvement observed in nearly 70% of approximately 400 HSCT-treated MS patients for at least 3 years.
• Significant reduction in gadolinium-enhancing lesions and a decline in brain atrophy progression post-HSCT.
• Transplant-related mortality has decreased over time, with no reported deaths since 2001.

Conclusions:

• Autologous HSCT can induce profound immunological changes, potentially restoring self-tolerance in MS patients.
• Optimal candidates for HSCT include young patients with active disease, rapid progression, and low disability scores unresponsive to standard treatments.
• Patient selection, timing of transplantation, and conditioning regimens are critical determinants of HSCT efficacy and safety in MS.